Thunder and lightning: immunotherapy and oncolytic viruses collide.

ABSTRACT: For the last several decades, the development of antitumor immune-based strategies and the engineering and testing of oncolytic viruses (OVs) has occurred largely in parallel tracks. Indeed, the immune system is often thought of as an impediment to successful oncolytic virus delivery and efficacy. More recently, however, both preclinical and clinical results have revealed potential synergy between these two promising therapeutic strategies. Here, we summarize some of the evidence that supports combining OVs with immuno-therapeutics and suggest new ways to mount a multipronged biological attack against cancers.

SUBMITTER: Melcher A 

PROVIDER: S-EPMC3129809 | biostudies-other | 2011 Jun

REPOSITORIES: biostudies-other